Robert J Gould Net Worth & Insider Trades
Robert J Gould - Interim President & CEO, Fulcrum Therapeutics, Inc
What is Robert J Gould's Net Worth?
The current estimated net worth of Fulcrum Therapeutics, Inc's Interim President & CEO, Robert J Gould, is estimated to be about $22.2M . Robert J Gould owns about 499,864 units of Fulcrum Therapeutics, Inc common stock. In the last 4 years at Fulcrum Therapeutics, Inc, Robert J Gould has sold an estimated value of $4.44M worth.
What is Robert J Gould's Past Insider Trading?
Robert J Gould's largest purchase order was 94,251 units , worth over $738.93K on April 5, 2022. Robert J Gould's largest sale order was 94,251 units , worth over $2.28M on April 5, 2022. In total, Robert J Gould has made about 20 transactions over 4 years of their time at Fulcrum Therapeutics, Inc. Robert J Gould usually trades in June, with the busiest year in 2020. The most recent transaction was a sale order of 6,766 units , worth over $101.49K on January 13, 2023.
Robert J Gould
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What was Robert J Gould's Salary in 2020?
As Interim President & CEO of Fulcrum Therapeutics, Inc, Robert J Gould has a total base salary of $650,000 . Robert J Gould received compensation valued at about $8,458,342 in 2020 after becoming Interim President & CEO.
What is Robert J Gould's' Mailing Address?
- Mailing address is C/o Epizyme, Inc. 400 Technology Square, 4th Floor Cambridge MA 02139 MA
What are Fulcrum Therapeutics, Inc's Past Insider Trades?
Fulcrum Therapeutics, Inc's most recent insider trade came on January 24, 2023 by Ra Capital Management Lp, Ra Capital Healthcare Fund Lp, Peter Kolchinsky and Rajeev Shah who bought 1,923,076 units worth $25M . In the last 4 years, insiders at Fulcrum Therapeutics, Inc have sold an estimated value of $7.48M and bought an estimated value of $52.6M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Robert J Gould, Interim President & CEO, Diego Cadavid, SVP Clinical Development, and Owen B Wallace, Chief Scientific Officer .
Fulcrum Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||